Skip to main navigation Skip to search Skip to main content

Withdrawal from high-dose tranylcypromine

  • F. Eyer
  • , E. Jetzinger
  • , R. Pfab
  • , T. Zilker
  • Technical University of Munich

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

A 34-year-old man with a history of multiple substance abuse (now abstinent for six years) became addicted to tranylcypromine, consuming up to 240 mg/day. After discontinuing the drug, he developed thrombocytopenia (52,000/ul) and delirium; there were no other anticholinergic signs. The delirium was unresponsive to haloperidol and diazepam. Intravenous administration of physostigmine (2 mg) on hospital day 6 resulted in prompt, but temporary, clearing of the delirium. Following a recurrence of the delirium after 30 minutes, he was started on an intravenous infusion of physostigmine (2 mg/hr) with good results. Physostigmine administration did not produce any cholinergic signs. By hospital day 8, he did not require any more physostigmine. Thrombocytopenia resolved on hospital day 9 without therapeutic intervention. On hospital day 10, the patient was asymptomatic and left the hospital on his own recognizance.

Original languageEnglish
Pages (from-to)261-263
Number of pages3
JournalClinical Toxicology
Volume46
Issue number3
DOIs
StatePublished - Mar 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Addiction
  • Delirium
  • Physostigmine
  • Thrombocytopenia
  • Tranylcypromine
  • Withdrawal

Fingerprint

Dive into the research topics of 'Withdrawal from high-dose tranylcypromine'. Together they form a unique fingerprint.

Cite this